|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
0.5090 USD |
+2.11% | -0.18% | -21.75% | |
Published on 05/28/2025 at 07:45
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Veru Reports Positive Safety Results From Phase 2B Quality Study |
07:45am |
RE |
|
Veru Inc. Reports Positive Safety Results from Phase 2b Quality Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone |
07:35am |
CI |
|
Veru Inc., Q2 2025 Earnings Call, May 08, 2025 |
May. 23 |
|
|
Veru Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2025 |
May. 08 |
CI |
|
B. Riley Cuts Price Target on Veru to $2 From $5, Keeps Buy Rating |
Mar. 07 |
MT |
|
Fat, not muscle: drugmakers in race for next weight-loss breakthrough |
Feb. 19 |
RE |
|
Next generation weight loss drugs aim to save muscle |
Feb. 19 |
RE |
|
Fat, not muscle: drugmakers in race for next weight-loss breakthrough |
Feb. 19 |
RE |
|
Oppenheimer Adjusts Price Target on Veru to $4 From $5, Keeps Outperform Rating |
Feb. 14 |
MT |
|
Veru Inc., Q1 2025 Earnings Call, Feb 13, 2025 |
Feb. 13 |
|
|
Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2024 |
Feb. 13 |
CI |
|
Veru’s Enobosarm Meets Primary Endpoint of Preserving Lean Body Mass in Phase 2b Study |
Jan. 27 |
MT |
|
Veru Inc. – Special Call |
Jan. 27 |
|
|
Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study |
Jan. 27 |
CI |
|
Veru Sells Female Condom Business to Riva Ridge Capital for $18 Million |
Dec. 31 |
MT |
|
Clients managed by Riva Ridge Capital Management LP acquired FC2 Female Condom® (Internal Condom) Business of Veru Inc. for $18 million. |
Dec. 30 |
CI |
|
Veru Inc. Reports Earnings Results for the Full Year Ended September 30, 2024 |
Dec. 16 |
CI |
|
Veru Inc. Auditor Raises ‘Going Concern’ Doubt |
Dec. 15 |
CI |
|
Veru Inc. Announces Meta-Analysis of Body Composition Data from Older Patients with Obesity Which Supports Potential for Enobosarm to Optimize Weight Loss At Obesityweek |
Nov. 05 |
CI |
|
Veru Inc., Q3 2024 Earnings Call, Aug 08, 2024 |
24-08-08 |
|
|
Earnings Flash (VERU) VERU Posts Q3 Revenue $4M, vs. Street Est of $3.5M |
24-08-08 |
MT |
|
Veru Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2024 |
24-08-08 |
CI |
|
Veru Inc. Appoints Loren Mark Katzovitz as Audit Committee and Compensation Committee |
24-08-02 |
CI |
|
Veru Inc.(NasdaqCM:VERU) added to Russell Small Cap Comp Value Index |
24-06-30 |
CI |
|
Veru Inc.(NasdaqCM:VERU) added to Russell Small Cap Completeness Index |
24-06-30 |
CI |
VERU: Dynamic Chart
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
More about the company
Buy
Last Close Price
0.5090USD
Average target price
3.250USD
Spread / Average Target
+538.51%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
